Oral uracil and Ftorafur plus leucovorin: Pharmacokinetics and toxicity in patients with metastatic cancer

Cancer Chemotherapy and Pharmacology

Volumn 46, Issue 5, 2000, Pages 351-356

  Ho, Dah H ^a   Covington, Wendy ^a   Brown, Nita ^a   Lin, San N ^b   Pazdur, Richard ^a   Huo, Yuang Yi ^a   Creaven, Patrick J ^c   Rustum, Youcef M ^c   Meropol, Neal J ^d   Lassere, Yvonne ^a   Kuritani, Jun ^e   Hayakawa, Tomohisa ^e  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Biomedical Polymers Research Bldg   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

5 FU; Ftorafur (tegafur); Pharmacology; Toxicity; UFT

Indexed keywords

FOLINIC ACID; TEGAFUR; UFT; URACIL;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HUMAN; KIDNEY CARCINOMA; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

EID: 0033729224     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000156     Document Type: Article

References (30)

1. Comprehensive criteria for assessing therapy-induced toxicity
2. Phase I-II studies of oral tegafur (Ftorafur)
3. 5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: A randomized Southwest Oncology Group study
4. Effect of uracil on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil
5. Effect of coadministration of uracil or cytosine on the antitumor activity of clinical doses of 1-(2-tetrahydro-furyl)-5-fluorouracil and level of 5-fluorouracil in rodents
6. Fluorinated pyrimidines
7. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-FU levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion
8. Bioavailability of high-dose oral leucovorin
9. Treatment of advanced-stage colorectal adenocarcinoma with fluorouracil and high-dose leucovorin calcium: A pilot study
10. Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate
11. UFT and leucovorin: A review of its clinical development and therapeutic potential in the oral treatment of cancer
12. Effect of uracil on metabolism of 5-fluorouracil in vitro
13. High pressure liquid chromatographic determination of Ftorafur [1-(tetrahydro-2-furanyl)-5-fluorouracil] and uracil in biologic materials after oral administration of uracil plus ftorafur
14. A phase I and pharmacokinetic study of oral uracil, Ftorafur, and leucovorin in patients with advanced cancer
15. Oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer
16. Cytotoxicity of fluorouridine and 5-fluorouracil in human T-lymphoblast leukemia cells: Enhancement by leucovorin
17. Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil
18. Phase I and II studies on a mixture of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil (UFT)
19. Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin
20. Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma
21. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma. A prospective randomized phase III trial
22. Biochemical modulation of fluorouracil: Evidence of significant improvement in survival and quality of life in patients with advanced colorectal carcinoma
23. 1-(2'-tetrahydrofuryl)-5-fluorouracil (FT-207)
24. 1-(2'-furanidyl-5-fluorouracil)
25. Hydroxylated metabolites of R,S-1-(tetrohydro-2-furanyl)-5-fluorouracil (ftorafur) in rats and rabbits